Peptide Initiative
Back to Pramlintide

Clinical trials

Every registered trial of Pramlintide

60 studies, 4 still enrolling.

Plain-Language Summary

Plain-language reading of the public trial registries.

In short

  • Pramlintide has a real but limited body of human research.
  • 60 registered studies in total.
  • 4 are still enrolling people, so this is active research, not just history.

What kind of research

  • 59 studies actually gave the peptide to volunteers and measured what happened. This is the kind of study that can show whether something works.
  • About 4,559 people took part in those.
  • A further 1 study only looked at records of people already taking it. These are counted separately because nobody was given the peptide for the study, so they cannot prove cause and effect.

A registered trial is a plan, not a result. Registration means a study was declared in advance; it says nothing about whether the peptide worked, and a trial can be registered and then abandoned.

Filter

Showing 60 of 60 trials for Pramlintide.

  • NCT07679516 Not Yet Recruiting15 enrolled2026

    Postprandial Regulation of Bone Perfusion in Healthy Individuals

    University of Copenhagen

    Healthy Adult Participants · Bone Physiology · Bone Blood Flow Regulation · Peptide Hormones

  • NCT07506369 Recruiting18 enrolled2026

    Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans

    University Hospital, Gentofte, Copenhagen

    Obesity & Overweight

  • NCT07340788 Not Yet Recruiting21 enrolled2026

    Amylin-Induced Migraine Attacks Without Aura

    Danish Headache Center

    Headache Disorders, Primary · Headache Disorders · Brain Diseases · Nervous System Diseases

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT07340775 Not Yet Recruiting21 enrolled2026

    Hypersensitivity to Amylin in Post-Traumatic Headache

    Danish Headache Center

    Headache Disorders, Secondary · Brain Diseases · Headache Disorders · Nervous System Diseases

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT06619015 Phase 2/3Withdrawn2025

    Tailoring Obesity Treatment Trial

    Esbjerg Hospital - University Hospital of Southern Denmark

    Obesity · Appetite Regulation · PreDiabetes

  • NCT06422325 Completed33 enrolled2024

    Two Way Crossover Closed Loop Study Insulin vs Insulin and Pramlintide

    Oregon Health and Science University

    Type 1 Diabetes

  • NCT06186063 Unknown20 enrolled2024

    The Role of Amylin in Bone Metabolism

    Filip Krag Knop

    Bone Diseases, Metabolic · Type 1 Diabetes

  • NCT06046417 Phase 2/3Unknown30 enrolled2023

    A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes

    McGill University Health Centre/Research Institute of the McGill University Health Centre

    type1diabetes · Diabetes Mellitus, Type 1

  • NCT05199714 Completed12 enrolled2022

    A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes

    McGill University Health Centre/Research Institute of the McGill University Health Centre

    Type 1 Diabetes

  • NCT04243629 Unknown26 enrolled2021

    Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System in Adults With Type 1 Diabetes

    McGill University

    Diabetes Mellitus, Type 1 · Type 1 Diabetes · Postprandial Hyperglycemia

  • NCT04163874 Completed36 enrolled2020

    Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas

    McGill University

    Type 1 Diabetes · Type 1 Diabetes Mellitus · Hyperglycemia, Postprandial

  • NCT03560960 Early Phase 1Active Not Recruiting57 enrolled2020

    Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease

    Boston University

    Alzheimer Disease · Mild Cognitive Impairment

  • NCT04252612 Early Phase 1Withdrawn2020

    Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study

    H. Lee Moffitt Cancer Center and Research Institute

    Cutaneous Squamous Cell Carcinoma

  • NCT04074317 Phase 2Completed18 enrolled2019

    Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D

    Xeris Pharmaceuticals

    Diabetes Mellitus, Type 1 · Insulin-dependent Diabetes Mellitus

  • NCT03993366 Completed8 enrolled2019

    Pramlintide and Fiasp Closed-Loop With a Simple Meal Announcement

    McGill University

    Type 1 Diabetes Mellitus

  • NCT03800875 Phase 2Completed24 enrolled2019

    Insulin-plus-pramlintide Closed-loop Strategy to Regulate Glucose Levels Without Carbohydrate Counting

    McGill University

    Diabetes Mellitus, Type 1

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT03916640 Phase 1Completed24 enrolled2019

    A Trial to Assess a Co-formulation of an Insulin Analog and Pramlintide in Subjects With Type 1 Diabetes Mellitus

    Adocia

    Type 1 Diabetes Mellitus

  • NCT03598075 Completed36 enrolled2018

    Amylin and CGRP Head to Head Provocation in Migraine Without Aura Patients

    Danish Headache Center

    Migraine Without Aura

  • NCT03547427 Terminated13 enrolled2018

    Glucagon Counterregulation in Type 1 Diabetes

    University of Virginia

    Type 1 Diabetes Mellitus

  • NCT02814123 Phase 2Completed28 enrolled2017

    Effect of Basal-Bolus Closed-Loop Co-Administration of Insulin and Pramlintide on Improving the Glycemic Control in Type 1 Diabetes

    McGill University

    Diabetes Mellitus, Type 1

    Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.

  • NCT02500979 Phase 1Completed34 enrolled2015

    Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus

    AstraZeneca

    Type 1 Diabetes Mellitus

  • NCT01839370 Completed9 enrolled2013

    Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus

    University of Virginia

    Diabetes Mellitus, Type 1

  • NCT01708044 Phase 1Completed32 enrolled2012

    Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM

    AstraZeneca

    Type 1 Diabetes

  • NCT01434862 Terminated2 enrolled2011

    Pramlintide Combined With Model Predictive Control Algorithm

    University of Virginia

    Type 1 Diabetes Mellitus

  • NCT01235741 Phase 2Terminated213 enrolled2011

    A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects

    AstraZeneca

    Obesity

  • NCT01137695 Phase 3Unknown40 enrolled2010

    Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus

    Cheryl Rosenfeld, DO

    Type 2 Diabetes Mellitus

  • NCT01841359 Phase 4Completed22 enrolled2010

    Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery

    Joslin Diabetes Center

    Hypoglycemia · Evidence of Previous Gastric Surgery

  • NCT01269047 Phase 4Completed37 enrolled2009

    Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia

    Albert Einstein College of Medicine

    Type 1 Diabetes

  • NCT01165944 Phase 1/2Withdrawn2009

    Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes Mellitus

    University of Colorado, Denver

    Diabetes Mellitus

  • NCT00950677 Phase 4Completed16 enrolled2009

    The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes

    Baylor College of Medicine

    Type 2 Diabetes

  • Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM

    University of Maryland, Baltimore

    Type 2 Diabetes

  • NCT00819234 Phase 2Completed274 enrolled2008

    Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin

    AstraZeneca

    Obesity

  • NCT00673387 Phase 2Completed636 enrolled2008

    Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects

    AstraZeneca

    Overweight · Obesity

  • NCT00690235 Phase 4Completed33 enrolled2007

    Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia

    University of Texas Southwestern Medical Center

    Schizophrenia · Schizoaffective Disorder · Diabetes · Weight Gain

  • NCT00460304 Completed12 enrolled2007

    The Effect of Pramlintide on Meal Time Insulin Bolus

    Diabetes Care Center

    Type 1 Diabetes

  • NCT00502138 Phase 4Completed12 enrolled2007

    A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes

    University Diabetes & Endocrine Consultants

    IDDM

  • NCT00505882 Phase 4Withdrawn2007

    Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes

    University of Texas Southwestern Medical Center

    Type 1 Diabetes

  • NCT00467649 Phase 4Completed112 enrolled2007

    A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00442767 Phase 4Completed8 enrolled2007

    Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus

    Montefiore Medical Center

    Type 1 Diabetes Mellitus

  • NCT00842075 Completed10 enrolled2006

    Pramlintide in Adolescents With Type 1 Diabetes

    University of Colorado, Denver

    Type 1 Diabetes

  • NCT00402077 Phase 2Completed258 enrolled2006

    A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects

    AstraZeneca

    Overweight · Obesity

  • NCT00392925 Phase 2Completed177 enrolled2006

    A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects

    AstraZeneca

    Overweight · Obesity

  • NCT00313183 Phase 2Completed12 enrolled2006

    A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus

    AstraZeneca

    Type 1 Diabetes Mellitus

  • NCT00291772 Phase 4Completed13 enrolled2006

    Continuous Subcutaneous Infusion of Pramlintide and Insulin

    Baylor College of Medicine

    Type 1 Diabetes

  • NCT00691158 Unknown10 enrolled2006

    A Study of the Functional Magnetic Resonance Imaging Response to Leptin and Pramlintide

    Oregon Health and Science University

    Obesity

  • NCT00240253 Phase 4Completed200 enrolled2005

    A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes

    AstraZeneca

    Type 2 Diabetes Mellitus

  • NCT00189514 Phase 2Completed210 enrolled2005

    A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

    AstraZeneca

    Obesity

  • NCT00229658 Completed1,297 enrolled2005

    An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes

    AstraZeneca

    Type 1 Diabetes Mellitus · Type 2 Diabetes Mellitus

  • NCT00112021 Phase 2Completed400 enrolled2005

    A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

    AstraZeneca

    Obesity

  • NCT00489645 Completed27 enrolled2005

    Effect of Hyperglycemia on Gastric Emptying Interactions With Pramlintide

    Ludwig-Maximilians - University of Munich

    Type 1 Diabetes

  • NCT00444561 Phase 2Completed184 enrolled2004

    Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects

    AstraZeneca

    Overweight · Obesity

  • NCT00206297 Phase 3Completed20 enrolled2003

    The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes

    Baylor College of Medicine

    Type 1 Diabetes

  • NCT00108004 Phase 3Completed400 enrolled2003

    Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus

    AstraZeneca

    Type 1 Diabetes Mellitus · Type 2 Diabetes Mellitus

  • NCT00107107 Phase 3Completed190 enrolled2002

    Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus

    AstraZeneca

    Diabetes Mellitus, Type 1

  • NCT00044707 Phase 2Completed24 enrolled2002

    Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide

    AstraZeneca

    Diabetes Mellitus, Non-Insulin-Dependent

  • NCT00042601 Phase 2Completed51 enrolled2002

    Evaluation of the Effect of Pramlintide on Satiety and Food Intake

    AstraZeneca

    Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2

  • NCT00206258 Phase 3Completed30 enrolled2002

    The Role of Amylin and Glucagon in T1DM

    Baylor College of Medicine

    Type 1 Diabetes

  • NCT00042471 Phase 2Completed75 enrolled2002

    Evaluation of the Bioavailability of Pramlintide

    AstraZeneca

    Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2

  • NCT00042458 Phase 3Completed296 enrolled2002

    Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control

    AstraZeneca

    Diabetes Mellitus, Type 1

  • The impact of pramlintide on top of semaglutide in obese people with prediabetes

    Esbjerg Sygehus

    Obesity (BMI ≧ 30kg/m2), Pre-diabetes (HbA1c 39-47 mmol/mol)

Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered in more than one registry is counted once. A study is listed when Pramlintide is named as an intervention. A registered trial is a plan, not a result — registration says nothing about whether the peptide worked.